SAI PARENTERALS LIMITED
Price Band
₹ 372 - ₹ 392
Bid Lot
38 Shares
SAI PARENTERALS LIMITED
24-Mar-2026 - 27-Mar-2026
Price Band
₹ 372 - ₹ 392
Minimum Investment
₹ 14896.00
Bid Lot
38 Shares
Shares
10,428,288
-
Face Value - Rs. 5/- Per Share
- Lisitng at NSE BSE
-
96,050 Application Required in Retail for 1 Time.
-
Registrar :
Bigshare Services Pvt. Ltd
IPO Details
Fresh Issue of Equity Shares aggregating to Rs. 285 Cr and Offer for sale of 3,157,880 Equity Shares
QIB
50%
(5,214,143 Shares)RS.204.39 CR
HNI 1
5%
(521,415 Shares)RS.20.44 CR @ 980 FORM 1X
HNI 2
10%
(1,042,829 Shares)RS.40.88 CR @ 1960 FORM 1X
Retail
35%
(3,649,901 Shares)RS.143.08 CR @ 96050 FORM 1X
BRLMs: Arihant Capital Markets Ltd
Timeline
-
24
Mar-2026
Open Date
-
27
Mar-2026
Close Date
-
30
Mar-2026
Basis of Allotment Date
-
01
Apr-2026
Initiation of Refunds
-
01
Apr-2026
Credit of Shares to Demat A/C
-
02
Apr-2026
IPO Listing Date
Subscription as on 27-Mar-2026 17:06
Category
Book Size
Subscription
QIB
1.73x
2,085,658
(₹81.76 Cr.)
3,610,266
(₹141.52 Cr.)
HNI (<10 LAKH)
0.24x
521,415
(₹20.44 Cr.)
124,184
(₹4.87 Cr.)
HNI2 (>10 LAKH)
3.56x
1,042,829
(₹40.88 Cr.)
3,707,318
(₹145.33 Cr.)
RETAIL
0.12x
3,649,901
(₹143.08 Cr.)
439,204
(₹17.22 Cr.)
Total
1.08x
7,299,803
7,880,972
Category
Book Size
Subscription
QIB
1.73x
2,085,658
(₹81.76 Cr.)
3,610,266
(₹141.52 Cr.)
HNI (<10 LAKH)
0.24x
521,415
(₹20.44 Cr.)
124,184
(₹4.87 Cr.)
HNI2 (>10 LAKH)
3.56x
1,042,829
(₹40.88 Cr.)
3,707,318
(₹145.33 Cr.)
RETAIL
0.12x
3,649,901
(₹143.08 Cr.)
439,204
(₹17.22 Cr.)
Total
1.08x
7,299,803
7,880,972
*Excluding Anchor
Total No. of Application Approx : ~7732 (0.08 Appwise)
HNI Cost
About Company
- q The Company was originally incorporated as Sai Parenteral’s Private Limited on January 12, 2001, in Hyderabad. Subsequently, on conversion into a public limited company the name was changed to Sai Parenteral’s Limited on January 17, 2022.
- q The Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. The company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets.
- q The Company’s portfolio includes formulation products across various therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology, with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments.
- q The company manufactures and sells Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market.
- q The company exports its products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors.
- q The company has 5 Manufacturing Facilities, of which 4 are in Hyderabad, Telangana and 1 manufacturing facility in Ongole, Andhra Pradesh, which is operated by its Subsidiary, Revat Laboratories.
- q The Manufacturing Facilities are spread across an aggregate area of 1,14,540 sq. ft. and have a combined installed capacity of 1,160 million units per annum on a single shift basis.
- q The company has developed a comprehensive, diversified portfolio of 302 pharmaceutical products, spanning both high-value and high-volume categories.
- q As of date, the company has 55 dossiers developed in-house, out of which 45 dossiers are approved by the FDA, Philippines and another 14 dossiers transferred by third-party CDMO customers under tech transfer agreements. Further, it plans to file 60 new product dossiers by FY 2028 across key Regulated and Semi-Regulated Markets.
- q As of December 31, 2025, the company supplied Branded Generic Formulation products to 10 countries through a network of 7 distributors.
Strengths
Competitive Strength
- Diversified generic formulations player with an established track record
- Strategically located and accredited Manufacturing Facilities
- Strong focus on CDMO business
- Well-established distribution network in India and overseas
- Track record of value-accretive acquisitions
- Experienced Promoters and Senior Management with extensive domain knowledge
Business Strategies
- Expansion into global injectable formulations market
- Capitalise on the CDMO opportunity by leveraging the manufacturing capabilities with enhanced R&D competencies
- Strengthening the presence in Regulated Markets through Noumed’s upcoming manufacturing facility in Adelaide, Australia
- Focus on new product development to drive future growth
- Grow the Branded Generic Formulations business by leveraging opportunities in the international markets
- Expand capabilities through strategic acquisitions
Company Promoters
Company Financials
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ? Crore | ||||
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (? Cr.) |
|---|---|---|
| 1 | Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| 2 | Establishment of a new R&D Centre; | 18.02 |
| 3 | Repayment / prepayment of certain outstanding borrowings | 14.30 |
| 4 | Working capital requirements | 33.00 |
| 5 | Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 35.64 |
| 6 | General corporate purposes | |
| Total | 211.76 |
How to Apply
Apply for IPO in few simple steps.
-
Step 1
Once you create your account, Login to Easy Investing.
-
Step 2
Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.
-
Step 3
Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).
-
Step 4
Enter your UPI ID and you will receive mandate on your UPI App.
-
Step 5
Once you accept the mandate, Application is submitted successful.
The Bidding Process
- Applying for an IPO is easier than ever with Easy Investing, in just a few clicks your application is processed. You can bid for any IPO through Easy Investing, the bidding process is simple and hassle free. Every company has a lot size decided & you can buy in multiples of the decided lot.
- If lot size is 15, then you have to bid for multiples of 15 share like 30,45,60 and so on.
- The maximum subscription amount for retail investors is 2 lakh.
- Any bid can be at a desired price or cut off price given by the company.
How to bid on App?
- Enter the number of shares you wish to buy, as per the lot size.
- You can apply at the cut off price set by the company or bid for a desired amount within the price band.
- Maximum three bids will be accepted.
- You then need to enter the UPI ID on Easy Investing’s IPO application form.
Investing using UPI
- You will immediately get a fund blocked request on your UPI for the submitted IPO application.
- The funds will be blocked in your bank account until allotment when it is debited.
- The limit for IPO application is Rs 2 lakh per transaction on UPI.
- On allotment of the shares, the money will be automatically debited.
- If the share aren’t allotted the blocked funds will reflect back into your account.
FAQs
Frequently Ask Question